PerkinElmer reports strong financial results for Q3 2011

PerkinElmer has published its financial report for the third quarter of 2011, during which the firm delivered a "strong" growth performance on a year-over-year basis.

The life sciences company generated revenues of $453.7 million (329.36 million pounds), up by eight percent compared to the year-ago period, while adjusted earnings per share and cash flow also increased.

Drivers of growth included its human and environmental health segments, with its strong adjusted gross margins proving sufficient to absorb investments in research and development and business capabilities.

Robert Friel, chairman and chief executive officer of PerkinElmer, said the firm is also seeing benefits from recent acquisition deals, with the imminent takeover of Caliper Life Sciences set to strengthen the business further.

"We continued to see good progress against our multi-year goal of expanding operating margins," he added.

Last month, the firm broadened its range of product offerings with the launch of NexION enhanced security software, a regulatory compliance tool for the pharmaceutical industry.